Related Experiment Video
Updated: Jun 19, 2026

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles
Published on: January 4, 2012
Targeted drug delivery in pancreatic cancer
Xianjun Yu1, Yuqing Zhang, Changyi Chen
1Michael E. DeBakey Department of Surgery, Molecular Surgeon Research Center, Elkins Pancreas Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
Abstract:
Effective drug delivery in pancreatic cancer treatment remains a major challenge. Because of the high resistance to chemo and radiation therapy, the overall survival rate for pancreatic cancer is extremely low. Recent advances in drug delivery systems hold great promise for improving cancer therapy. Using liposomes, nanoparticles, and carbon nanotubes to deliver cancer drugs and other therapeutic agents such as siRNA, suicide gene, oncolytic virus, small molecule inhibitor, and antibody has been a success in recent preclinical trials. However, how to improve the specificity and stability of the delivered drug using ligand or antibody directed delivery represent a major problem. Therefore, developing novel, specific, tumor-targeted drug delivery systems is urgently needed for this terrible disease. This review summarizes the current progress on targeted drug delivery in pancreatic cancer and provides important information on potential therapeutic targets for pancreatic cancer treatment.
Insights
Targeted drug delivery systems show promise for improving pancreatic cancer treatment outcomes. Developing specific, tumor-targeted methods is crucial due to resistance to conventional therapies.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Pancreatic cancer exhibits high resistance to chemotherapy and radiation, leading to poor survival rates.
- Current drug delivery methods face challenges in specificity and stability for effective pancreatic cancer treatment.
Purpose of the Study:
- To review recent advancements in targeted drug delivery for pancreatic cancer.
- To highlight potential therapeutic targets for improving treatment efficacy.
Main Methods:
- Review of preclinical studies utilizing nanoparticles, liposomes, and carbon nanotubes for drug delivery.
- Analysis of targeted delivery strategies using ligands and antibodies.
Main Results:
- Nanoparticle-based systems have shown success in preclinical trials for delivering various therapeutic agents.
- Improving specificity and stability of targeted delivery remains a key challenge.
Conclusions:
- Novel, tumor-targeted drug delivery systems are urgently needed for pancreatic cancer.
- Further research into ligand/antibody-directed delivery can enhance therapeutic outcomes.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Site-Targeted Drug Delivery Systems: Polymeric Carriers
